Antibiotic, Bactericidal, Fluoroquinolone, Hepatic enzyme inhibitor
Brand Names
Orbax®
Drug Information
Pharmacology
Fluoroquinolone antibiotic concentration dependent bactericidal.
Contraindications
General
- Contraindicated in patients with known sensitivity to this type of drug.
- Use with caution in patients with possible CNS disorders-may cause CNS stimulation and seizures.
- Use only when benefit outweighs the risk during pregnancy as safety has not been established.
- Administer orbifloxacin with caution in the presence of hepatic insufficiency/impairment.
General
- WARNING: Extra label use in food animals is prohibited by the FDA.
Dog
- Contraindicated in small and medium breed dogs 2 – 8 months old and large, giant breeds up to 1 year old due to the risk of articular cartilage damage.
Cat
- DO NOT EXCEED 7.5 mg/kg BODY WEIGHT PER DAY IN CATS
Adverse Effects
General
- Vomiting, loss of appetite, lethargy are possible side effects.
- Anaphylactic reactions, facial swelling, ataxia and seizures are also possible.
- Cartilage damage may occur-see contraindications.
Cat
- The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such products should be used with caution in cats. Blindness has also been reported post-approval in cats. In some cases, blindness has been temporary.
- DO NOT EXCEED 3.4 mg/lb (7.5 mg/kg) BODY WEIGHT PER DAY IN CATS.
Interactions
General Interactions
- Increased liver enzymes, BUN, creatinine and decreases in hematocrit have been reported in human taking fluoroquinolones. Clinical significance is unclear.
Category Interactions
Aminoglycoside Antibiotic
- Synergism is possible but unpredictable with aminoglycosides.
Antacid
- Antacids may bind to orbifloxacin, preventing it’s absorption. Separate by 2 hours.
Anticoagulant
- Concurrent administration of fluoroquinolones may increase the action of oral anticoagulants.
Cephalosporin antibiotic
- Synergism is possible but unpredictable with third generation cephalosporins.
Hepatic enzyme inhibitor
- Metabolism of other cytochrome P-450 metabolized drugs may be altered.
Penicillin / related
- Synergism is possible but unpredictable with certain penicillins.
Drug Interactions
Aminophylline
- If given concurrently, may increase serum levels of theophylline.
CycloSPORINE
- Fluoroquinolones may increase the risk of nephrotoxicity from systemic CycloSPORINE.
Nitrofurantoin
- Nitrofurantoin may antagonize activity of orbifloxacin.
Sucralfate
- Sucralfate may bind to orbifloxacin, preventing it’s absorption. Separate by 2 hours.
Theophylline
- May inhibit theophylline metabolism and result in toxicity.
Available Forms
Human
- None
Veterinary – General
- Tablets- 5.7 mg in btls of 250 tabs, 22.7 mg in btls of 250 and 68 mg in btls of 100; Orbax® Approved for dog and cat. Oral suspension – in 20 mL bottles; ORBAX® Oral Suspension. Approved for dog and cat.
Comments